Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Facon

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Leukemia|August 1, 1997
POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cellsC Rose, M Zandecki, M C Copin, et al.
La Revue De Medecine Interne|February 16, 2005
[Thalidomide: mechanisms of action and new insights in hematology]X Leleu, J B Micol, R Guieze, et al.
Blood|June 1, 1992
Double-intensive therapy in high-risk multiple myelomaJ L Harousseau, N Milpied, J P Laporte, et al.
La Revue De Medecine Interne|January 1, 1993
[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums]C Mathiot, B Grosbois, J L Teillaud, et al.
American Journal of Hematology|February 1, 1995
Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)T Facon, J F Menard, J L Michaux, et al.
Journal of Clinical Immunology|January 1, 1993
Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myelomaC Mathiot, J L Teillaud, M Elmalek, et al.
Leukemia Research|December 29, 1999
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphologyJ E Goasguen, M Zandecki, C Mathiot, et al.
Blood|July 27, 2000
patients with the description of a new scoring system and its validation on 253 other patientsP Morel, M Monconduit, D Jacomy, et al.
Annals of Hematology|March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myelomaA Palumbo, F Davies, M Kropff, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Thalidomide in patients with advanced multiple myelomaI Yakoub-Agha, P Moreau, S Leyvraz, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Leukemia|August 1, 1997
POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cellsC Rose, M Zandecki, M C Copin, et al.
La Revue De Medecine Interne|February 16, 2005
[Thalidomide: mechanisms of action and new insights in hematology]X Leleu, J B Micol, R Guieze, et al.
Blood|June 1, 1992
Double-intensive therapy in high-risk multiple myelomaJ L Harousseau, N Milpied, J P Laporte, et al.
La Revue De Medecine Interne|January 1, 1993
[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums]C Mathiot, B Grosbois, J L Teillaud, et al.
American Journal of Hematology|February 1, 1995
Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)T Facon, J F Menard, J L Michaux, et al.
Journal of Clinical Immunology|January 1, 1993
Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myelomaC Mathiot, J L Teillaud, M Elmalek, et al.
Leukemia Research|December 29, 1999
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphologyJ E Goasguen, M Zandecki, C Mathiot, et al.
Blood|July 27, 2000
patients with the description of a new scoring system and its validation on 253 other patientsP Morel, M Monconduit, D Jacomy, et al.
Annals of Hematology|March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myelomaA Palumbo, F Davies, M Kropff, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Thalidomide in patients with advanced multiple myelomaI Yakoub-Agha, P Moreau, S Leyvraz, et al.
Pageof 13